Calliditas Therapeutics AB (CALT)
|Net Income (ttm)||-3.50M|
|Trading Day||April 16|
|Day's Range||26.80 - 27.25|
|52-Week Range||19.00 - 38.00|
Calliditas Therapeutics (NASDAQ: CALT) has submitted a marketing application to the FDA seeking approval for Nefecon, an oral formulation targeting down-regulation of IgA1 for primary IgA Nephropathy (I...
STOCKHOLM, Feb. 18, 2021 /PRNewswire/ -- "On November 8, 2020, we announced positive topline readout of Part A of our Phase 3 pivotal trial, NefIgArd. The results were statistically significant and clin...
Calliditas Therapeutics AB (NASDAQ: CALT) has dosed that first patient in the global open-label extension part of Phase 3 study (dubbed as NefIgArd) that will offer a 9-month treatment with Nefecon to a...
STOCKHOLM, Jan. 26, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depositary Shares ("...
STOCKHOLM, Jan. 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enrolled for the global Phase...
STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021. The nomination committee, which is appointed in accordan...
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstratio...
STOCKHOLM, Nov. 11, 2020 /PRNewswire/ -- On November 12, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the third quarter 2020. Calliditas will also h...
Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nef...
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (OMX Nasdaq: CALTX) (NASDAQ: CALT) ("Calliditas") today announced positive topline results from Part A of the global Phase 3 clinical t...
STOCKHOLM, Sept. 30, 2020 /PRNewswire/ -- During September, Calliditas Therapeutics AB (publ) has allotted 111,250 common shares within the company's warrant program issued in 2017. Thus, as of Septembe...
Successful capital raise on NASDAQ STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- "In June we successfully closed a $90m U.S.
STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the second quarter 2020.
Calliditas Therapeutics (NASDAQ: CALT) shares are trading higher on Tuesday after Jefferies initiated coverage on the stock with a Buy rating and a price target of $44 per share.
Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephro... [Read more...]
Drug Manufacturers-Specialty & Generic
|IPO Date |
Jun 5, 2020
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for CALT stock is "Strong Buy." The 12-month stock price forecast is 49.60, which is an increase of 84.52% from the latest price.